このエントリーをはてなブックマークに追加


ID 56183
JaLCDOI
フルテキストURL
72_4_427.pdf 2.38 MB
著者
Sekimizu, Masahiro Department of Pediatrics, Nagoya Medical Center
Fujimoto, Junichiro Department of Pathology, National Center for Child Health and Development
Takimoto, Tetsuya Center for Clinical Research and Development, National Center for Child Health and Development
Tsurusawa, Masahito Advanced Medical Research Center, Aichi Medical University
Horibe, Keizo Department of Clinical Research Center
Sunami, Shosuke Department of Pediatric Hematology Oncology, Japanese Red Cross Narita Hospital
抄録
Pediatric patients with lymphoblastic lymphoma are generally treated using the Berlin-Frankfurt-Munster (BFM) 90 protocol, which is the standard treatment strategy for pediatric acute lymphoblastic leukemia, and have a favorable outcome. However, this intense regimen includes high total doses of anthracycline and alkylating agents, and is known to cause late complications. We therefore planned a clinical trial to examine the efficacy and safety of a modified BFM regimen. We expect that this phase II, nationwide multicenter trial will help to establish an effective and safer standard therapy for stage I/II pediatric lymphoblastic lymphoma.
キーワード
pediatrics
limited stage
lymphoblastic lymphoma
efficacy
safety
Amo Type
Clinical Study Protocol
出版物タイトル
Acta Medica Okayama
発行日
2018-08
72巻
4号
出版者
Okayama University Medical School
開始ページ
427
終了ページ
430
ISSN
0386-300X
NCID
AA00508441
資料タイプ
学術雑誌論文
言語
英語
著作権者
CopyrightⒸ 2018 by Okayama University Medical School
論文のバージョン
publisher
査読
有り
PubMed ID